Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease

References

• Collins PL, Chanock RM, Murphy BR. Fields Virology Knipe DM, Howley PM (Eds). Raven Press, NY, USA, 1443–1486 (2001).
   Google Scholar
• Simoes EA. Respiratory syncytial virus infection. Lancet 354,847–852 (1999).
   PubMed Web of Science ®Google Scholar
• Brandt CD, Kim HW, Arrobio JO et al. Epidemiology of respiratory syncytial virus infection in Washington DC. III. Composite analysis of eleven consecutive yearly epidemics. Am. J. Epiderniol. 98,355–364 (1973).
   Google Scholar
• Belshe RB, Van Voris LP, Mufson MA, Hyler L. Epidemiology of severe respiratory syncytial virus infections in Huntington, West Virginia. Med. J. 77, 49–52 (1981).
   Google Scholar
• Shay DK, Holman RC, Newman RD et al. Bronchiolitis-associated hospitalizations among US children 1980-1996. JAMA 282,1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Brooks AM, McBride JT, McConnochie KM et al. Predicting deterioration in previously healthy infants hospitalized with respiratory syncytial virus infection. Pediatrics 104,463–467 (1999).
   Google Scholar
• Groothuis JR, Simoes EA, Levin MJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl. J. Med. 329,1524–1530 (1993).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Fouillard L, Mouthon L, Laporte J et al Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Tranplant. 9,97–100 (1992).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treaner JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40,115–119 (1992).
   PubMed Web of Science ®Google Scholar
• Han LL, Alexander JP, Anderson U. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179,25-30 (1999).
   Google Scholar
• Falsey AR. Respiratory syncytial virus infection in older persons. Vaccine 16, 1775–1778 (1998).
   PubMedGoogle Scholar
• Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13,371–384 (2000).
   PubMed Web of Science ®Google Scholar
• Hall CB, Geiman JM, Biggar R et al. Respiratory syncytial virus infections within families. N Engl. J. Med. 294,414–419 (1976).
   PubMed Web of Science ®Google Scholar
• Rietveld E, De Jonge HC, Polder JJ et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr. Infect. Dis. 23(6), 523–529 (2004).
   Google Scholar
• Murphy BR, May SL, Kulkarni AB et al. An update on approaches to the development of respiratory syncytial virus and parainfluenza virus Type 3 vaccines. Virus Res. 32,13–36 (1994).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182(5), 1331–1342 (2000).
   Google Scholar
• •Safety evaluation of a recombinant live attenuated respiratory syncytial virus (RSV) vaccine in infants.
   Google Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140,543–546 (1986).
   PubMedGoogle Scholar
• Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. j Pediatr. 126(2), 212–219 (1995).
   PubMed Web of Science ®Google Scholar
• Bruhn FW, Mokrohisky ST, McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J. Pediatr. 90(3), 382–386 (1977).
   Google Scholar
• Kim HVV, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epiderniol. 89, 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• •• Original manuscript describing the outcome of formalin-inactivated RSV vaccine (FIRSV) trial.
   Google Scholar
• Chin J, Magoffin RU, Shearer RA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epiderniol. 89, 449–463 (1969).
   Google Scholar
• •• Original manuscript describing the outcome of a FIRSV trial.
   Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J Epiderniol. 89,405–421 (1969).
   Google Scholar
• ••Original manuscript describing theoutcome of a FIRSV trial.
   Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, Joyner JVV, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. 1. Epiderniol. 89,435-448 (1969).
   Google Scholar
• ••Original manuscript describing theoutcome of FIRSV vaccine trial.
   Google Scholar
• Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. 1. Gen. Virol. 82,2881-2888 (2001).
   Google Scholar
• ••Reassessment of lung sections of childrenwho died of enhanced respiratory disease (ERD) in 1967. Highlights the role of neutrophils in ERD pneumonia in children.
   Google Scholar
• Tanner El, Gray JD, Rebello PV, Gamble DR. Terminal bronchopneumonia. A bacteriological and histological study of 111 necropsies. 1. Hyg. (Lmid.) 67, 477–484 (1969).
   Google Scholar
• Almuneef MA, Baltimore RS, Farrel PA, Reagan-Cirincione P, Dembry LM. Molecular typing demonstrating transmission of Gram-negative rods in a neonatal intensive care unit in the absence of a recognized epidemic. Clin. Infect. Dis. 32,220–227 (2001).
   Google Scholar
• Guenthner SH, Hendley JO, Wenzel RP. Gram-negative bacilli as nontransient flora on the hands of hospital personnel. 1 Clin. Microbiol. 25,488-490 (1987).
   Google Scholar
• Niederman MS. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. Sernin. Respir. Infect. 5,173–184 (1990).
   Google Scholar
• Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin-8 gene region in UK families. Thorax 55, 1023–1027 (2000).
   Google Scholar
• Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. j I17717711fla 163,2816–2820 (1999).
   Google Scholar
• Sheeran P, Jafri H, Carubelli C et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr. Infect. Dis.j 18,115–122 (1999).
   PubMed Web of Science ®Google Scholar
• Tal G, Mandelberg A, Dalal I et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. 1. Infect. Dis. 189(11), 2057–2063 (2004).
   Google Scholar
• Graham BS. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am. j Resp. Grit. Care Med. 152, S63—S66 (1995).
   Google Scholar
• Openshaw PJ. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. 1 Resp. Grit. Care Med. 152, S59—S62 (1995).
   Google Scholar
• Graham BS, Henderson GS, Tang YW et al. Priming immunization determines T-helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. 1. Irninunol. 151, 2032–2040 (1993).
   Google Scholar
• ••First demonstration of a T-helper (Th)2bias in the lungs of BALB/c mice with ERD. Interestingly, a similar result is observed after immunization with purified F-protein.
   Google Scholar
• Hancock GE, Speelman DJ, Heers K et al. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol. 70,7783–7791 (1996).
   PubMed Web of Science ®Google Scholar
• Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Irninunol. 4, 493–498 (1992).
   Google Scholar
• Srikiatkhachorn A, Chang W, Braciale TJ. Induction of Thl and Th2 responses by respiratory syncytial virus attachment glycoprotein is epitope and MHC independent. J Virol. 73,6590-6597 (1999).
   Google Scholar
• Alwan WH, Record FM, Openshaw PJM. CD4+ T-cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T-cells. Clin. Exp. Immunol. 88, 527–536 (1992).
   Google Scholar
• Tang YW, Graham BS. Anti-interleukin-4 treatment after immunization modulates cytokine expression, reduces illness and increases cytotoxic T-lymphocyte activity in mice challenged with RSV. J Cilia. Invest. 94,1953-1958 (1994).
   Google Scholar
• •Describes a modulatory role for cytotoxic T-lymphocytes (CTLs) on the Th bias of ERD pneumonia.
   Google Scholar
• Warns M, Tsou C, Erdman DD, Zaki SR, Anderson U. Respiratory syncytial virus infection in BALM mice previously immunized with formalin inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 70,2852-2860 (1996).
   Google Scholar
• Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp. Med. 188, 1967–1972 (1998).
   Google Scholar
• Connors M, Giese NA, Kulkarni AB et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALM mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.j Vim]. 68,5321–5325 (1994).
   Web of Science ®Google Scholar
• ••Demonstrates a role for interleukin (IL)-4and IL-10 in ERD pneumonia.
   Google Scholar
• Murphy BR, Prince GA, Walsh EE et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. I Cilia. Microbiol. 24,197–202 (1986).
   PubMed Web of Science ®Google Scholar
• •• Highlights the poor neutralizing capacity of FIRSV-induced antibody.
   Google Scholar
• Polack FP, Teng MN, Collins PL et al. A role for immune complexes in enhanced respiratory syncytial virus disease. I Exp. Med. 196,859–865 (2002).
   PubMed Web of Science ®Google Scholar
• •• Demonstrates a role for immune complexes in ERD bronchoconstriction in mice and in lung sections from affected children.
   Google Scholar
• Connors M, Kulkarni AB, Firestone CY et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALM mice is abrogated by depletion of CD4+ T-cells. I Vim]. 66,7444–7451 (1992).
   Google Scholar
• ••Demonstrates a role for CD4+ T-cells inERD pneumonia.
   Google Scholar
• Lukacs NW, Glovsky MM, Ward PA. Complement-dependent immune complex-induced bronchial inflammation and hyper-reactivity. Am. I Physiol. Lung Cell Mol. Physiol. 280(3), L512—L518 (2001).
   Google Scholar
• Humbles AA, Lu B, Nilsson CA et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406(6799), 998–1001 (2000).
   Google Scholar
• Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. j II77177111701. 169(10), 5926–5933 (2002).
   Google Scholar
• Hawlisch H, Wills-Karp M, Karp CL, Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. MoL IrmnunoL 41(2-3), 123–131 (2004).
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Sdence 282 (5397), 2258–2261 (1998).
   Google Scholar
• Karp CL, Grupe A, Schadt E et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nature IrmnunoL 1 (3), 221–226 (2000).
   Google Scholar
• De Swart, Kuilten T, Timmerman HH et aL Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleultin-13-associated hypersensitivity to subsequent infection. J. Virol. 76,11561-11569 (2002).
   Google Scholar
• Hussell T, Baldwin CJ, O'Garra A, Openshaw PJ. CD8+ T-cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. II77177111701. 27(12), 3341–3349 (1997).
   Google Scholar
• •Describes a modulatory role for CTLs on the Th bias of ERD pneumonia.
   Google Scholar
• Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T-lymphocytes downregulate T-helper cell Type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186(3), 421–432 (1997).
   Google Scholar
• •Describes a modulatory role for CTLs on the Th bias of ERD pneumonia.
   Google Scholar
• Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson U. Respiratory syncytial virus G and/or SH protein alters Thl cytokines, natural killer cells and neutrophils responding to pulmonary infection in BALB/c mice. J. ViroL 73, 7099–7107 (1999).
   PubMed Web of Science ®Google Scholar
• Kalina WV, Woolums AR, Berghaus RD, Gershwin U. Formalin-inactivated bovine RSV vaccine enhances a Th2-mediated immune response in infected cattle. Vaccine 22,1465–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Hussell T, Georgiou A, Sparer TE et al. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J. IrmnunoL 161(11), 6215–6222 (1998).
   Google Scholar
• •Highlights the effect of genetic variability on the pulmonary granulocytic response during ERD.
   Google Scholar
• Prince GA, Jenson AB, Hemming VG et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. ViroL 57, 721–728 (1986).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Sotnikov A, Paradiso PR et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7, 533–540 (1989).
   PubMed Web of Science ®Google Scholar
• Gershwin U, Schelegle ES, Gunther RA et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16,1225–1236 (1998).
   PubMed Web of Science ®Google Scholar
• Norrby E, Enders-Ruckle G, ter Meulen V. Difference in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J. Infect. Dis. 132,262–269 (1975).
   Google Scholar
• Merz DC, Scheid A, Choppin PVV. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J. Exp. Med. 151,275–288 (1980).
   Google Scholar
• Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion- inhibiting activity. J.Microbiol. 26(8),1595–1597 (1988).
   Google Scholar
• •Demonstration of functional differences in the antibodies elicited by FIRSV versus live infection.
   Google Scholar
• Kulkarni AB, Morse HC III, Bennink JR, Yewdell JW, Murphy BR. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T-cells. j ViroL 67(7), 4086–4092 (1993).
   Google Scholar
• Connors M, Collins PL, Firestone CY et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10, 475–484 (1992).
   PubMed Web of Science ®Google Scholar
• Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine 8,497–502 (1990).
   Google Scholar
• Johnson TR, Teng MN, Collins PL, Graham BS. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.J ViroL 78,6024–6032 (2004).
   PubMed Web of Science ®Google Scholar
• Bembridge GP, Rodriguez N, Garcia-Beato R et al. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J. Gen. Virol. 81, 2519–2523 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Wenzke DR, McAuliffe JM et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus Type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus Type 3 vector backbone. J. ViroL 76(3), 1089–1099 (2002).
   Google Scholar
• Bembridge GP, Garcia-Beato R, Lopez JA et al. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G-protein. j IrmnunoL 161,2473–2480 (1998).
   PubMed Web of Science ®Google Scholar
• Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. ViroL 75(22), 11079–11087 (2001).
   Google Scholar
• Karron RA, Wright PF, Belshe BB et al. Identification of a recombinant live-attenuated respiratory syncytial virus vaccine candidate that is attenuated in infants. J. Infect. Dis. (2004). In press.
   Google Scholar
• Carter CH, Conway TJ, Cornfeld D et al. Serologic response of children to inactivated measles vaccine. JAMA 179, 848–853 (1962).
   PubMedGoogle Scholar
• Nader PR, Honwitz MS, Rousseau J. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72,22-28 (1968).
   Google Scholar
• Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202, 1075–1079 (1967).
   PubMed Web of Science ®Google Scholar
• Martin DB, Weiner LB, Nieburg PI, Blair DC. Atypical measles in adolescents and young adults. Ann. Int. Med. 90,877–881 (1970).
   Google Scholar
• Mc Lean DM, Katy's GD, Hingston J et al. Atypical measles following immunization with killed measles vaccine. Cand. Med. Assoc.j 103,743–744 (1970).
   Google Scholar
• Polack FP, Auwaerter PG, Lee SH et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibodies. Nature Med. 5, 629–634 (1999).
   PubMed Web of Science ®Google Scholar
• •Demonstrates a role for immune complexes in atypical measles.
   Google Scholar
• Kim HW, Leikin SL, Arrobio J et al. Cell- mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10,75–78 (1976).
   PubMed Web of Science ®Google Scholar
• Kraus PJ, Cherry JD, Carney JM, Naiditch MJ, O'Connor K. Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am.J.Dis. Child 134,567–571 (1980).
   Google Scholar
• Polack FP, Hoffman SJ, Moss WJ, Griffin DE. Altered synthesis of interleukin-12, Type 1 and Type 2 cytokines in rhesus macaques during measles and atypical measles. J Infect. Dis. 185,13-19 (2002).
   Google Scholar
• Polack FP, Lee SH, Permar S et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nature Med. 6,776–781 (2000).
   PubMed Web of Science ®Google Scholar
• Polack FP, Hoffman SI Crujeiras Griffin, G. DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nature Med. 9(9), 1209–1213 (2003).
   Google Scholar
• ••Demonstrates an important role for affmitymaturation in promoting protective antibody responses against measles.
   Google Scholar